{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T10:06:17Z","timestamp":1767953177143,"version":"3.49.0"},"reference-count":22,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,8,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> There is a need for new agents to treat metastatic breast cancer (MBC) in patients for whom anthracycline therapy has failed or is contraindicated. This study was conducted to assess the efficacy and safety of the novel antineoplastic, the epothilone B analog ixabepilone, in patients with MBC previously treated with an adjuvant anthracycline. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients were age \u2265 18 years and had received a prior anthracycline-based regimen as adjuvant treatment. Ixabepilone as first-line metastatic chemotherapy was administered as a 40 mg\/m<jats:sup>2<\/jats:sup> intravenous infusion during 3 hours every 3 weeks. The primary efficacy end point was objective response rate (ORR). Secondary efficacy end points included duration of response, time to response, time to progression, and survival. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> All 65 patients were assessable for response. Their median age was 52 years (range, 33 to 80 years). ORR was 41.5% (95% CI, 29.4% to 54.4%), median duration of response was 8.2 months (95% CI, 5.7 to 10.2 months), and median time to response was 6 weeks (range, 5 to 17 weeks). Median survival was 22.0 months (95% CI, 15.6 to 27.0 months). Treatment-related adverse events were manageable and mostly grades 1\/2: the most common of these (other than alopecia) was mild to moderate neuropathy, which was primarily sensory and mostly reversible in nature. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Ixabepilone is efficacious and has a predictable and manageable safety profile in women with MBC previously treated with an adjuvant anthracycline. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2006.09.7535","type":"journal-article","created":{"date-parts":[[2007,7,3]],"date-time":"2007-07-03T00:51:09Z","timestamp":1183423869000},"page":"3415-3420","source":"Crossref","is-referenced-by-count":185,"title":["Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy"],"prefix":"10.1200","volume":"25","author":[{"given":"Henri","family":"Roch\u00e9","sequence":"first","affiliation":[{"name":"From the Institut Claudius Regaud, Toulouse; Institut Bergonie, Bordeaux; Centre Eugene Marquis, Rennes; Centre Jean Perrin, Clermont-Ferrand, France; Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al\u2013H\u00f4pital Notre-Dame, Montreal, Quebec, Canada; Comitato Etico (Istituto di Ricovero e Cura a Carattere Scientifico) di Roma, IFO-Istituto Regina Elena, Rome, Italy; Dana-Farber Cancer Institute, Boston, MA; Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Department of Oncology; Weill..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Yelle","sequence":"additional","affiliation":[{"name":"From the Institut Claudius Regaud, Toulouse; Institut Bergonie, Bordeaux; Centre Eugene Marquis, Rennes; Centre Jean Perrin, Clermont-Ferrand, France; Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al\u2013H\u00f4pital Notre-Dame, Montreal, Quebec, Canada; Comitato Etico (Istituto di Ricovero e Cura a Carattere Scientifico) di Roma, IFO-Istituto Regina Elena, Rome, Italy; Dana-Farber Cancer Institute, Boston, MA; Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Department of Oncology; Weill..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cognetti","sequence":"additional","affiliation":[{"name":"From the Institut Claudius Regaud, Toulouse; Institut Bergonie, Bordeaux; Centre Eugene Marquis, Rennes; Centre Jean Perrin, Clermont-Ferrand, France; Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al\u2013H\u00f4pital Notre-Dame, Montreal, Quebec, Canada; Comitato Etico (Istituto di Ricovero e Cura a Carattere Scientifico) di Roma, IFO-Istituto Regina Elena, Rome, Italy; Dana-Farber Cancer Institute, Boston, MA; Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Department of Oncology; Weill..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Mauriac","sequence":"additional","affiliation":[{"name":"From the Institut Claudius Regaud, Toulouse; Institut Bergonie, Bordeaux; Centre Eugene Marquis, Rennes; Centre Jean Perrin, Clermont-Ferrand, France; Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al\u2013H\u00f4pital Notre-Dame, Montreal, Quebec, Canada; Comitato Etico (Istituto di Ricovero e Cura a Carattere Scientifico) di Roma, IFO-Istituto Regina Elena, Rome, Italy; Dana-Farber Cancer Institute, Boston, MA; Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Department of Oncology; Weill..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Bunnell","sequence":"additional","affiliation":[{"name":"From the Institut Claudius Regaud, Toulouse; Institut Bergonie, Bordeaux; Centre Eugene Marquis, Rennes; Centre Jean Perrin, Clermont-Ferrand, France; Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al\u2013H\u00f4pital Notre-Dame, Montreal, Quebec, Canada; Comitato Etico (Istituto di Ricovero e Cura a Carattere Scientifico) di Roma, IFO-Istituto Regina Elena, Rome, Italy; Dana-Farber Cancer Institute, Boston, MA; Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Department of Oncology; Weill..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Sparano","sequence":"additional","affiliation":[{"name":"From the Institut Claudius Regaud, Toulouse; Institut Bergonie, Bordeaux; Centre Eugene Marquis, Rennes; Centre Jean Perrin, Clermont-Ferrand, France; Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al\u2013H\u00f4pital Notre-Dame, Montreal, Quebec, Canada; Comitato Etico (Istituto di Ricovero e Cura a Carattere Scientifico) di Roma, IFO-Istituto Regina Elena, Rome, Italy; Dana-Farber Cancer Institute, Boston, MA; Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Department of Oncology; Weill..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Kerbrat","sequence":"additional","affiliation":[{"name":"From the Institut Claudius Regaud, Toulouse; Institut Bergonie, Bordeaux; Centre Eugene Marquis, Rennes; Centre Jean Perrin, Clermont-Ferrand, France; Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al\u2013H\u00f4pital Notre-Dame, Montreal, Quebec, Canada; Comitato Etico (Istituto di Ricovero e Cura a Carattere Scientifico) di Roma, IFO-Istituto Regina Elena, Rome, Italy; Dana-Farber Cancer Institute, Boston, MA; Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Department of Oncology; Weill..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[{"name":"From the Institut Claudius Regaud, Toulouse; Institut Bergonie, Bordeaux; Centre Eugene Marquis, Rennes; Centre Jean Perrin, Clermont-Ferrand, France; Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al\u2013H\u00f4pital Notre-Dame, Montreal, Quebec, Canada; Comitato Etico (Istituto di Ricovero e Cura a Carattere Scientifico) di Roma, IFO-Istituto Regina Elena, Rome, Italy; Dana-Farber Cancer Institute, Boston, MA; Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Department of Oncology; Weill..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Vahdat","sequence":"additional","affiliation":[{"name":"From the Institut Claudius Regaud, Toulouse; Institut Bergonie, Bordeaux; Centre Eugene Marquis, Rennes; Centre Jean Perrin, Clermont-Ferrand, France; Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al\u2013H\u00f4pital Notre-Dame, Montreal, Quebec, Canada; Comitato Etico (Istituto di Ricovero e Cura a Carattere Scientifico) di Roma, IFO-Istituto Regina Elena, Rome, Italy; Dana-Farber Cancer Institute, Boston, MA; Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Department of Oncology; Weill..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Peck","sequence":"additional","affiliation":[{"name":"From the Institut Claudius Regaud, Toulouse; Institut Bergonie, Bordeaux; Centre Eugene Marquis, Rennes; Centre Jean Perrin, Clermont-Ferrand, France; Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al\u2013H\u00f4pital Notre-Dame, Montreal, Quebec, Canada; Comitato Etico (Istituto di Ricovero e Cura a Carattere Scientifico) di Roma, IFO-Istituto Regina Elena, Rome, Italy; Dana-Farber Cancer Institute, Boston, MA; Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Department of Oncology; Weill..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"From the Institut Claudius Regaud, Toulouse; Institut Bergonie, Bordeaux; Centre Eugene Marquis, Rennes; Centre Jean Perrin, Clermont-Ferrand, France; Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al\u2013H\u00f4pital Notre-Dame, Montreal, Quebec, Canada; Comitato Etico (Istituto di Ricovero e Cura a Carattere Scientifico) di Roma, IFO-Istituto Regina Elena, Rome, Italy; Dana-Farber Cancer Institute, Boston, MA; Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Department of Oncology; Weill..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Ezzeddine","sequence":"additional","affiliation":[{"name":"From the Institut Claudius Regaud, Toulouse; Institut Bergonie, Bordeaux; Centre Eugene Marquis, Rennes; Centre Jean Perrin, Clermont-Ferrand, France; Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al\u2013H\u00f4pital Notre-Dame, Montreal, Quebec, Canada; Comitato Etico (Istituto di Ricovero e Cura a Carattere Scientifico) di Roma, IFO-Istituto Regina Elena, Rome, Italy; Dana-Farber Cancer Institute, Boston, MA; Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Department of Oncology; Weill..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Cur\u00e9","sequence":"additional","affiliation":[{"name":"From the Institut Claudius Regaud, Toulouse; Institut Bergonie, Bordeaux; Centre Eugene Marquis, Rennes; Centre Jean Perrin, Clermont-Ferrand, France; Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al\u2013H\u00f4pital Notre-Dame, Montreal, Quebec, Canada; Comitato Etico (Istituto di Ricovero e Cura a Carattere Scientifico) di Roma, IFO-Istituto Regina Elena, Rome, Italy; Dana-Farber Cancer Institute, Boston, MA; Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Department of Oncology; Weill..."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-90003-20"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.2015"},{"key":"R3","unstructured":"Bollag DM, McQueney PA, Zhu J, et al: Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. Cancer Res 55:2325,1995-2333,"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200351819"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1021\/bi0121611"},{"key":"R6","unstructured":"Lee FY, Borzilleri R, Fairchild CR, et al: BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429,2001-1437,"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.7304"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Cont\u00e9 P, Thomas E, Martin M, et al: Phase II study of ixabepilone in patients (pts) with taxane-resistant metastatic breast cancer (MBC): final report. J Clin Oncol 24:566s,2006,  (suppl; abstr 10505)","DOI":"10.1200\/jco.2006.24.18_suppl.10505"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.2397"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.5964"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600645"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.027"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1413"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00122-7"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.2174\/1568011023354489"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.2820"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.024"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.7802"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Bunnell CA, Klimovsky J, Thomas E: Final efficacy results of a phase I\/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. J Clin Oncol 24:568s,2006,  (suppl; abstr 10511)","DOI":"10.1200\/jco.2006.24.18_suppl.10511"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Llombart-Cussac A, Baselga J, Manikhas G, et al: Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): Preliminary efficacy and safety data. J Clin Oncol 23:25s,2005,  (suppl; abstr 586)","DOI":"10.1200\/jco.2005.23.16_suppl.586"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2006.09.7535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:07:50Z","timestamp":1653509270000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.09.7535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,10]]},"references-count":22,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2007,8,10]]}},"alternative-id":["10.1200\/JCO.2006.09.7535"],"URL":"https:\/\/doi.org\/10.1200\/jco.2006.09.7535","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,10]]}}}